The Combination of Allogenic eNK Cells With IL-2 Delay Colorectal Cancer Xenograft Development In Vivo, Which Is Not Improved by Including the PD-1 Blocking Antibody Pembrolizumab. The gene discussed is IL2; the disease is colorectal cancer.